Indications : התוויות

Therapeutic indications                                                                                         The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure
Adults:                                                                                                         levels no different from those of the general population. No alteration of daily dosage or frequency of
Ondansetron Baxter 2mg/ml is indicated for the management of nausea and vomiting induced by                     dosing is required.
cytotoxic chemotherapy and radiotherapy. Ondansetron Baxter 2mg/ml is indicated for the
prevention and treatment of post-operative nausea and vomiting (PONV).                                    4.3   Contra-indications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Paediatric Population:                                                                                          Concomitant use with apomorphine (see section 4.5).
Ondansetron Baxter 2mg/ml is indicated for the management of chemotherapy-induced nausea
and vomiting (CINV) in children aged ≥6 months, and for the prevention and treatment of PONV in           4.4    Special Warnings and Precautions for Use
children aged ≥ 1 month.
Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to